Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000176225 | SCV000227842 | uncertain significance | not provided | 2015-03-06 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001352198 | SCV001546735 | uncertain significance | Cone-rod dystrophy 13; Leber congenital amaurosis 6 | 2020-02-22 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C0"). This variant has not been reported in the literature in individuals with RPGRIP1-related conditions. ClinVar contains an entry for this variant (Variation ID: 195617). This variant is present in population databases (rs760334377, ExAC 0.02%). This sequence change replaces alanine with valine at codon 1126 of the RPGRIP1 protein (p.Ala1126Val). The alanine residue is moderately conserved and there is a small physicochemical difference between alanine and valine. |
Genome- |
RCV001800512 | SCV002045503 | uncertain significance | Leber congenital amaurosis 6 | 2021-11-07 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV001800513 | SCV002045514 | uncertain significance | Cone-rod dystrophy 13 | 2021-11-07 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003362709 | SCV004080110 | uncertain significance | Inborn genetic diseases | 2023-08-02 | criteria provided, single submitter | clinical testing | The c.3377C>T (p.A1126V) alteration is located in exon 21 (coding exon 21) of the RPGRIP1 gene. This alteration results from a C to T substitution at nucleotide position 3377, causing the alanine (A) at amino acid position 1126 to be replaced by a valine (V). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |